Want to join the conversation?
$LH said its LabCorp Diagnostics segment net revenue for 2Q16 was $1.66Bil, up 5.4% YoverY, helped by organic volume growth, price, mix and tuck-in acquisitions. For Covance Drug Development segment, net revenue rose 12.2% to $722.4MM, helped by broad-based demand, partially offset by the negative impact of foreign currency translation.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?